ArticleInternational journal of clinical and experimental pathology2014
Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient's survival.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next-generation sequencing analysis.FEBS open bio · 2026Article
- Knockdown of Plexin C1 induces epithelial-to-mesenchymal transition and confers resistance to multikinase inhibitors in hepatocellular carcinoma cells.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- The expression and prognostic value ofTranslational cancer research · 2024Article
- STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Cancer stem-like cells contribute to paclitaxel resistance in esophageal squamous cell carcinoma.International journal of clinical and experimental pathology · 2022Article
- Exosomal microRNAs in colorectal cancer: Overcoming barriers of the metastatic cascade (Review).International journal of molecular medicine · 2021Review
- Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.Molecular and cellular biochemistry · 2021Article
- Meta-Analysis of Esophageal Cancer Transcriptomes Using Independent Component Analysis.Frontiers in genetics · 2021Article
- Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.Cells · 2020Review
- Research progress on the relationship between lung cancer drug-resistance and microRNAs.Journal of Cancer · 2019Review
- Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.Therapeutic advances in vaccines and immunotherapy · 2019Review
- Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.Oncogenesis · 2018Article
- Expression of CCR6 in esophageal squamous cell carcinoma and its effects on epithelial-to-mesenchymal transition.Oncotarget · 2017Article
- Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.Cancer science · 2017Article
- Modulation of E-cadherin expression promotes migration ability of esophageal cancer cells.Scientific reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epithelial-mesenchymal transition (EMT) is an essential step in invasion and metastasis of human cancers. Identification of EMT status would help us to properly understand the mechanism of cancer metastasis and progression. In the present study, tissue microarray and immunohistochemical staining of two important markers, E-cadherin and Vimentin, were used to characterize the EMT status in human esophageal cancer. We selected the appropriate cut-off values of expression levels of E-cadherin and Vimentin, and found 63 out of 105 cases of esophageal cancers underwent EMT. And we also found that in the subgroup with (T₃ + T₄), the ratio of patients undergoing EMT was significantly higher than that in the subgroup with (T₁ + T₂) (P = 0.0097), and in the subgroup with metastasis, the ratio of patients undergoing EMT was significantly higher than that in the subgroup with no metastasis (P = 0.0253). The log-rank survival analysis showed that the overall survival rate of the patients undergoing EMT was significantly poorer than that of the patients with wide type status (P = 0.0278, HR = 2.470, 95% CI: 1.971~2.970). In the COX model analysis, we also found that the EMT status of the esophageal cancer patients could be used as an independent risk factor for the prediction of prognosis of this malignancy (P = 0.026, HR = 2.306, 95% CI: 1.103~4.824). Thus, our present study successfully established a method by using tissue microarray and the markers, E-cadherin and Vimentin, to conveniently and properly identify the EMT status in human esophageal cancer, and revealed that the EMT status significantly associated with invasion, metastasis and prognosis in this malignancy.
Indexed as
Identifiers
25400779PMC4230146W288335600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.